RESULTS: 653 men underwent mpMRI, of which 344 underwent prostate biopsy resulting in a 47% biopsy avoidance rate, of which 83.2% were reported as PIRADS 2. Demographics included median (with interquartile range) age (67; 62-72 years), prostate specific antigen (PSA; 8.6; 6-12 ng/ml), prostate volume (36.5; 30-51 ml) and PSA density (0.24; 0.15-0.32 ng/ml3) respectively. A trend toward higher PSA, PSA density and lower prostate volume and age was observed with higher PIRADS score. A 69.8% cancer detection rate was observed, 60.5% of which were considered to have clinically significant disease. Targeted biopsies resulted in a higher proportion of positive biopsies (70%) compared to template (4.2%) and combined targeted and template (36.4%) approaches. Higher PIRADS scores were associated with clinically significant disease, no matter the biopsy approach.
INTRODUCTION AND OBJECTIVES: The PRI-MUS
TM (Prostate Risk Identification for Micro-Ultrasound) protocol was developed in 2016 1 to identify suspicious areas seen by the ExactVu TM microultrasound imaging platform. Since its development, multiple clinical trials and studies have demonstrated the utility of the PRI-MUS protocol for targeted prostate biopsy, however little prospective validation data on overall accuracy has been reported.
METHODS: 142 subjects were biopsied using the ExactVu micro-ultrasound system (Exact Imaging, Markham, Canada) from January to May 2018 at the Ordensklinikum Linz (Linz, Austria) with PSA scores ranging from 0.55 to 178.05 ng/mL and varying DRE results. Suspicious areas were assessed in real-time using PRI-MUS and a TRUS biopsy was performed in the same session under microultrasound guidance. A total of 143 biopsies were completed by 5 providers (1 subject underwent 2 biopsy procedures). Results from pathology were then compared with the image findings.
RESULTS: Biopsy pathology confirmed a cancer diagnosis in 79/142 (56%) of the subjects. 48/79 (60%) subjects had clinically significant cancer with a Gleason sum of 7 or higher. The PRI-MUS protocol had an area under the receiver-operator characteristic (AUC) of 0.79, with 100% sensitivity, 30% specificity and 100% negative predictive value for clinically significant cancer. As has been noted in other studies, PRI-MUS was more accurate for clinically significant cancer than for all cancer, demonstrating 0.69 AUC, 92% sensitivity, 30% specificity and a 76% negative predictive value for all cancer.
CONCLUSIONS: Micro-ultrasound and the PRI-MUS protocol are useful tools to detect cancer and are more accurate in the detection of clinically significant cancer. This technology holds promise for reducing the high false-negative rate of prostate biopsy, without relying on multi-modality, multi-specialty solutions like mpMRI. (MRI) ; however, US stands apart as a fast, radiation-free, and cost-effective modality. Two methods of ultrasound used are transabdominal pelvic (PUS) and transrectal (TRUS) ultrasound, with the latter considered to be more accurate, but more invasive. This study aims to compare the accuracy of PUS to TRUS sizing and is the largest study to date to do so.
METHODS: We performed a single-center, retrospective study of 199 patients with PUS and TRUS prostate sizing between January 1, 2012 and August 31, 2017. Prostate volume was derived from ellipsoid volume calculation (length x width x height x P/6) using dimensions measured on US. Sizes obtained by PUS and TRUS were compared by calculating the Pearson correlation coefficient. We utilized the two sample z test to analyze for differences in prostate size between the US modalities. This univariate analysis was done for the whole sample population as well as for specific groupings of variables.
RESULTS: A total of 199 patients had both PUS and TRUS prostate sizing. Median age was 63, median BMI was 27, 32 (16%) were white, 112 (56%) were black, and 35 (18%) were Hispanic. Median PSA value prior to PUS was 8.0 ng/mL. Average time between each US modality was 29 days, with 98 (49%) patients having TRUS within 31 days. Median size by PUS was and TRUS were both 52 cm , with 149 (75%) patients having a 25% difference between PUS and TRUS estimations.
CONCLUSIONS: There were no statistically significant differences between prostate size estimated by PUS versus TRUS. Additionally, there were no statistically significant differences in size when grouped by prostate volume, time between US exams, and BMI. As PUS is non-invasive, it should be the preferred modality for estimating prostate size.
